thumbnail image
  • SCIENCE
  • CLINICAL TRIALS
  • PARTNERS 
    • PHARMA
    • PAYORS
    • HEALTH SYSTEMS
  • NEWS
  • OUR COMPANY 
    • AmDTx
    • OUR TEAM
    • CAREERS
  • CONTACT US
  • …  
    • SCIENCE
    • CLINICAL TRIALS
    • PARTNERS 
      • PHARMA
      • PAYORS
      • HEALTH SYSTEMS
    • NEWS
    • OUR COMPANY 
      • AmDTx
      • OUR TEAM
      • CAREERS
    • CONTACT US
    • SCIENCE
    • CLINICAL TRIALS
    • PARTNERS 
      • PHARMA
      • PAYORS
      • HEALTH SYSTEMS
    • NEWS
    • OUR COMPANY 
      • AmDTx
      • OUR TEAM
      • CAREERS
    • CONTACT US
    • …  
      • SCIENCE
      • CLINICAL TRIALS
      • PARTNERS 
        • PHARMA
        • PAYORS
        • HEALTH SYSTEMS
      • NEWS
      • OUR COMPANY 
        • AmDTx
        • OUR TEAM
        • CAREERS
      • CONTACT US
      • SCIENCE
      • CLINICAL TRIALS
      • PARTNERS
        • PHARMA
        • PAYORS
        • HEALTH SYSTEMS
      • NEWS
      • OUR COMPANY
        • AmDTx
        • OUR TEAM
          • OUR TEAM
          • CHIEF EXECUTIVE OFFICER
          • CHIEF TECHNOLOGY OFFICER
          • CHIEF OF CONTENT
          • CHIEF FINANCIAL OFFICER
          • VP PHARMACEUTICALS
          • ASSISTANT TO THE CEO
        • CAREERS
      • CONTACT US
        Go Back

        Milo Chao, Branding & Marketing

        LinkedIn
        LinkedIn
        More Details

        I was previously the Chief Strategy Officer at TBWA-Shanghai where I oversaw the planning function across TBWA, Digital Arts Network, The Integer Group, and BEING. I joined TBWA after nine years at DDB, where, in my most recent role, I was Head of Planning for Greater China.

        In the past, I have worked at Rapp Collins and Grey, and I have a long and highly regarded career having worked in New York, Dallas, Singapore, Hong Kong, Beijing, Tokyo and Shanghai on clients as diverse as Dell, Sony, Toyota, Mars, Philips, Unilever and PepsiCo.

        ​I hold degrees from Northwestern University’s Kellogg School of Management, Hong Kong University of Science and Technology, Northwestern University’s Medill School of Journalism, Johns Hopkins University-Nanjing University School for Chinese and American Studies and State University of New York at Binghamton.

        • To prevent, measure, and treat mental illness, we develop digital theragnostics personalised with objective and scalable biomarkers.

          ↓↓↓
        • Proprietary Technology

          Our software uses facial photoplethysmography (PPG) and deep neural networks to personalise safe and effective treatments, while providing real time data on real world efficacy. The resulting gamified "measure-treat-measure" system has been clinically proven to reduce the risk of mental illness in cancer patients, as well as alleviate anxiety in young adults when compared to placebo in multiple clinical trials.

          Learn More
        • AI-based theragnostics every patient can access.

          Digitally-enabled pharmacotherapy, theragnostics and mental health endpoints.

          Pharma

          Giving policyholders access to clinically-validated mental wellness tools.

          Payors

          Supporting personalised healthcare on site and at home.

           

          Health Systems
        • Subscribe to the newsletter.

          Monthly updates on our progress tackling the world's mental health crisis.

          Subscribe

        CONTACT US

        TERMS OF USE

        PRIVACY POLICY

        Effective and accessible healthcare for every human.

          All Posts
          ×
          Cookie Use
          We use cookies to ensure a smooth browsing experience. By continuing we assume you accept the use of cookies.
          Learn More